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Abstract: Alzheimer disease (AD) is the most prevalent neurodegenerative disorder in elderly people. Patients with AD appear to be
particularly at risk for cognitive deterioration following anesthesia. Some in vitro studies suggest that exposure to general anesthesia
(GA) promotes the AD process. On the other hand, there are no clinical studies that clearly demonstrate that GA is a cause of cognitive
dysfunction in patients with probable AD. The aim of this research was to discuss the relation between postoperative cognitive
dysfunction (POCD) and AD according to the literature. In vivo studies examining AD biomarkers postoperatively and in vitro studies
exploring amyloid-β (Aβ) converge to indicate that anesthetics could affect AD pathogenesis, either directly or indirectly. Careful
evaluation of the mental state should be mandatory for all elderly patients undergoing GA. Long-term prospective, randomized clinical
studies are required to examine the relationship between POCD and AD.
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1. Introduction
There are many comorbid diseases that become more
common with ageing (1). Alzheimer disease (AD), which
was described by Alois Alzheimer in 1907, is the most
common form of progressive, irreversible dementia in
the elderly (1–3). It affects more than 25 million people
worldwide; without a major therapeutic breakthrough, its
prevalence is expected to increase more than 100 million
by 2050 (1–5).
Worldwide, 200 million patients undergo surgery
under anesthesia each year. As overall life expectancy
has increased, an increasing number of elderly patients
are undergoing anesthesia. In addition, elderly surgical
patients are more likely to have preexisting AD or be at
risk for developing it. It is well known that POCD is an
important problem for the elderly and patients with
probable AD (6–11). On the other hand, there are no
clinical studies that clearly demonstrate that general
anesthesia (GA) causes cognitive dysfunction in patients
with probable AD.
This review article discusses the relationship between
POCD and AD based on what we found in the currently
published literature.
2. Alzheimer disease or probable Alzheimer disease
The diagnosis of AD is based on a positive history,
neurological examination, and neuropsychological tests.
The National Institute of Neurological and Communicative
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Disorders and the Stroke-Alzheimer’s Disease and Related
Disorders Association Work Group criteria for diagnosing
probable AD are documentation of dementia by clinical
examination, deficits in two or more cognitive domains,
absence of other systemic disorders, and progressive
worsening of memory (12). Another commonly used
criterion, according to the DSM IV (Diagnostic and
Statistical Manual of Mental Disorders, 4th edition), is the
loss of at least two of the following: orientation, memory,
judgment, language, or calculation (13).
AD patients usually present with a subtle onset of
memory loss, followed by slowly progressive dementia over
the course of several years. The course of AD is variable,
and cognitive impairment, personality change, psychotic
symptoms, incontinence, gait and motor disturbances,
seizures, and myoclonus may occur. Memory impairment
is progressive and destructive. AD also increases the
mortality of the affected population. Life expectancy varies
between 4 and 8 years after diagnosis (14–22).
A definitive diagnosis of AD can be made only by
autopsy of a patient’s brain. This neuropathological
evaluation reveals diffuse atrophy of the cerebral cortex,
signifying loss of neurons. Diagnostic lesions are found
on histopathological evaluation of most affected areas of
the brain, which reveal the presence of large numbers of
extracellular β-amyloid (βA) plaques and intracellular,
neurofibrillary tangles (NFTs) (1–3,21–23). Even though
plaques and NFTs are often found in cognitively normal
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elderly people, the plaques are denser and the NFTs are
more widely distributed in patients with AD, according to
standardized histological assessments (23).
Predisposing factors for AD are not yet fully
understood. However, genes might play an important
role in its development. Early-onset familial forms of AD
have an autosomal dominant inheritance linked to APP,
PSEN1, and PSEN2 genes, whereas the most common
sporadic form of AD, which occurs after the age of 60,
has thus far been consistently associated with only the
APOE gene (24).
Causes of sporadic AD are likely to be multifactorial
(25). Numerous environmental factors have been proposed
as causes of AD. One pervasive environmental factor is
drug exposure. Most people receive general anesthetic
agents at some point during their lives, and whether these
drugs are contributing factors in the pathogenesis of AD is
not clear (1–4,12,19,22,26–28).
There is a comprehensive need for treating symptoms
related to AD. The most widely employed strategy is
symptomatic treatment with cholinergic agents, such as
acetylcholine (ACh), and monoamines, neuropeptides,
and metabolic enhancers (14,16,17,19).
3. What is general anesthesia?
Around 200 million patients worldwide undergo anesthesia
for major surgery every year (20). The objective of GA
is to produce analgesia, amnesia, hypnosis, and muscle
relaxation to facilitate surgery. Inhaled general anesthetics
are highly lipid soluble and have low affinity of blood; hence
they rapidly permeate the brain in high concentrations.
General anesthetics and other drugs administered during
anesthesia interact with the central cholinergic system
(CCS). Anesthetic modulation of cholinergic transmission
has profound effects on brain function via a cascade of
synaptic and postsynaptic events by binding both nicotinic
and muscarinic receptors. GA decreases ACh release and
depression of cholinergic transmission facilitates the
desirable effects of general anesthetics such as loss of
consciousness, movement, pain perception, and memory.
However, sometimes these effects become persistent
(26,29–31). Anesthesia affects not only consciousness but
also hemodynamics, thermoregulation, immunity, and
pulmonary function. All these effects may adversely affect
brain function. Furthermore, because of an underlying
illness or condition that requires surgery, the surgery itself
and its associated inflammatory process, nonanesthetic
drugs, or physiology may induce postoperative cognitive
problems (32).

Delirium is defined as sudden decline in attention and
focus perception, and altered level of consciousness.
Onset is usually within 13 days of surgery and may last
up to a week. Preoperative risk factors predisposing to
delirium include aging, lower education level, reoperation,
polypharmacy and drug interaction, alcohol and
sedative‐hypnotic withdrawal, endocrine and metabolic
compromise, impaired vision and hearing, sleep deficiency,
anxiety, depression, and dementia. Delirium is a common
but undiagnosed complication in the elderly after major
surgery. The incidence ranges from 9% to 87%, depending
on both the patient and surgical conditions (33–36).
POCD is remarkably common, especially in the
elderly; it can vary from mild and short-lived to severe
and permanent. Immediate postoperative incidence is
10% to 25%. After several months, it can be detected in
5% to 15% (36–38). Symptoms include memory, attention,
concentration, and planning problems related to executive
functions. POCD is usually reported later, after the patient
has left the hospital (8–11,33,38,39).
Elderly patients with dementia are at increased risk of
POCD following surgery (34).
The cholinergic system is involved in cognition arousal
and sensory gating. Impaired cholinergic transmission
is thought to play an important role in the development
of delirium. Total serum anticholinergic activity has
consistently been shown to be associated with delirium
in older patients. Therefore, augmentation of cholinergic
function would theoretically present itself as a target for
intervention with a view to reducing both the incidence
and severity of delirium. There are reports of successful
use of cholinesterase inhibitor to treat delirium (26,31,40).
Furthermore, anesthesia, neurotoxicity, inflammation,
and stress might be conducive to POCD and delirium.
Other conditions such as preexisting impairment,
comorbid illness, and current events may also play a role
in the development of postoperative cognitive problems.
Some practitioners have reported that the type of surgery
(e.g., hip fracture) and intraoperative factors (e.g.,
hypotension, desaturation) are contributing factors for
POCD (38–42).
Assessing patients for cognitive change requires both
pre- and postoperative testing. There are many tests and
test batteries to determine executive functions during
the postoperative period (41,42). However, there is no
consensus as to the magnitude of cognitive change that
should be considered clinically relevant; determination
and quantification of any change require a baseline
measure (38–43).

4. Cognitive problems following anesthesia
Postoperative cognitive problems are mainly delirium and
postoperative cognitive dysfunction (POCD) (6–11,13).

5. Cognitive dysfunction and AD
The most common postoperative complication in the
elderly is POCD (33,36,38,39). Patients with AD are
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considered to be particularly at risk for some of the
cognitive side effects of anesthesia. Some in vitro and in
vivo studies suggest that anesthetics promote and intensify
the neuropathogenesis of AD (44–49). However, some
researchers reported no association between anesthesia
and AD (28,50–53).
Bufill et al. (54) have demonstrated an inverse
correlation between the age of AD onset and cumulative
exposure to anesthesia before the age of 50. Wilsson
et al. (55) have withdrawn AD biomarkers from the
cerebrospinal fluid (CSF) before and after surgery and
anesthesia. They also reported that CSF total tau and tau
phosphorilated at Thr181 P-tau were significantly elevated
following surgery, but Aβ42 did not change. However,
whether this was due to the surgery or the anesthesia is not
clear. Similarly, Polates et al. (56) reported that a cognitive
decline significantly decreased the level of βA peptides and
markedly increased tau protein concentrations in the CSF
of patients 6 months after cardiac surgery.
Possible mechanisms by which inhaled anesthetics
could induce synaptic dysfunction and neuronal apoptosis
and ultimately produce cognitive decline in the aged
brain are by increasing the intracellular βA level and βA
and tau aggregation and disrupting intracellular calcium
homeostasis. In the amyloid and tau pathways, β-site
amyloid precursor protein-cleaving enzyme (BACE)
generates c-terminal fragments (CTFβ) from membranebound amyloid precursor protein. Cleavage of the CTFβ
by δ-secretase releases βA monomers into the cytosolic
and extracellular space. Anesthetic exposure increases
the levels of BACE and δ-secretase, thereby increasing
the levels of intracellular βA and decreasing CTFβ levels
(57,58). Inhaled anesthetics also interact with the βA
monomers to promote the formation of small, soluble
oligomers (46). These oligomers further associate to form
fibrils and extracellular plaque, which have been found to
be increased in mice with transgenic AD after exposure
to halothane. These effects activate caspase, initiating
apoptosis and cleaving the adaptor protein GGA3,
which is required for BACE lysosomal degradation. This
results in increased BACE levels, further enhancing the
production of βA, and introducing a vicious circle that
ensures apoptosis. Microtubule (MT)-bound tau becomes

hyperphosphorylated and detached by anesthetics and
hypothermia, resulting in tau aggregates and decreased
MT stability. Anesthetics increase cytosolic calcium via
several mechanisms. For example, inhaled anesthetics
activate the endoplasmic reticulum (ER) membrane
inositol 1,4,5-trisphosphate receptors (IP3Rs) and
ryanodine receptors (RyRs), increasing cytosolic calcium
and depleting ER calcium (59,60). These drugs also activate
the sarcoplasmic/ER calcium adenosine triphosphatase
(ATPase) (SERCA1), further enhancing the activity of ER
calcium release pathways. Further increases in cytosolic
calcium levels might be caused by activation of N-methyld-aspartate receptors and inhibition of calcium clearance
via plasma membrane calcium ATPase. Increased cytosolic
calcium loads the mitochondria with calcium, releasing
cytochrome-c, further contributing to apoptosis. Finally,
ER calcium depletion via the above mechanisms can
induce apoptosis directly. Both the βA/tau and calcium
pathways contribute to synaptic dysfunction and apoptotic
responses (61).
Studies have indicated that POCD is associated with
changes in biomarkers similar to those seen in AD (56,61).
6. Conclusion
General anesthetics and other drugs administered during
anesthesia interact with the CCS, and degenerative diseases
of the brain are associated with deficits in the cholinergic
system. Preclinical studies exploring the impact of
anesthetics on βA and tau and clinical studies examining
AD biomarkers postoperatively converge to indicate that
anesthetics could affect AD pathogenesis, either directly
or indirectly.
Careful preoperative mental state evaluation is
mandatory for all elderly patients scheduled for surgery
under GA. Long-term epidemiological prospective studies
(designed to control for critical variables such as type of
surgery, duration of procedure, age at exposure, preexisting
comorbid disease, anesthetic technique, and patient
temperature) and randomized controlled trials (using
biomarkers or neuro-imaging modalities) are required to
examine the relationship between general anesthesia and
AD to confirm such an association.
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